PriceTargets.com logo

DarioHealth - DRIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.03
  • Forecasted Upside: 398.62%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.21 As of 11/30/2023 01:00 AM ET
▼ -0.08 (-6.20%)

This chart shows the closing price for DRIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DarioHealth Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRIO

Analyst Price Target is $6.03
▲ +398.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for DarioHealth in the last 3 months. The average price target is $6.03, with a high forecast of $8.00 and a low forecast of $4.10. The average price target represents a 398.62% upside from the last price of $1.21.

This chart shows the closing price for DRIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in DarioHealth. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2023Alliance Global PartnersLower TargetBuy ➝ Buy$5.45 ➝ $4.10Low
7/25/2023Stifel NicolausLower TargetBuy$9.00 ➝ $6.00Low
5/12/2023Alliance Global PartnersLower Target$7.50 ➝ $6.00Low
5/12/2023Craig HallumLower Target$14.00 ➝ $8.00Low
11/16/2022Alliance Global PartnersLower TargetBuy ➝ Buy$9.15 ➝ $7.50Low
8/18/2022AegisLower TargetBuy$20.00 ➝ $15.00Low
8/16/2022CowenLower TargetOutperform$18.00 ➝ $14.00Low
8/16/2022CowenLower TargetOutperform$18.00 ➝ $14.00Low
5/16/2022CowenBoost TargetNA$18.00N/A
5/16/2022CowenBoost Target$14.00 ➝ $18.00High
5/13/2022Alliance Global PartnersUpgradeNeutral ➝ Buy$8.75High
4/18/2022CowenLower Target$30.00 ➝ $14.00High
4/18/2022CowenLower Target$30.00 ➝ $14.00Medium
1/26/2022AegisLower TargetBuy$28.00 ➝ $25.00High
1/20/2022Alliance Global PartnersLower Target$15.50 ➝ $11.50High
8/26/2021Lifesci CapitalReiterated RatingOutperformHigh
8/19/2021AegisLower TargetBuy$35.00 ➝ $28.00Low
8/17/2021Alliance Global PartnersLower TargetNeutral$15.25 ➝ $12.75Low
5/24/2021Alliance Global PartnersLower TargetNeutral$18.25 ➝ $15.25Medium
5/18/2021Stifel NicolausLower TargetReduce ➝ Buy$30.00 ➝ $25.00High
4/22/2021CowenInitiated CoverageOutperform$31.00High
3/22/2021Stifel NicolausInitiated CoverageBuy$30.00High
2/25/2021Cantor FitzgeraldInitiated CoverageOverweight$35.00Medium
2/8/2021AegisBoost TargetBuy$25.00 ➝ $35.00Low
2/1/2021Alliance Global PartnersDowngradeBuy ➝ Neutral$15.60 ➝ $22.25Low
8/17/2020AegisInitiated CoverageBuy$25.00High
8/13/2020Craig HallumBoost TargetBuy$8.00 ➝ $17.00High
6/22/2020ThinkEquityInitiated CoverageBuy$10.00Low
5/13/2020Craig HallumBoost TargetBuy$7.00 ➝ $8.00Low
3/18/2020Craig HallumLower TargetBuy$12.00 ➝ $7.00High
12/4/2019Craig HallumLower TargetBuy$20.00 ➝ $12.00High
6/6/2019Craig HallumInitiated CoverageBuy$1.50High
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2023
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2023
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/1/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 4 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2023

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

DarioHealth logo
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Read More

Today's Range

Now: $1.21
Low: $1.18
High: $1.30

50 Day Range

MA: $2.01
Low: $1.00
High: $3.39

52 Week Range

Now: $1.21
Low: $0.68
High: $6.78

Volume

89,443 shs

Average Volume

147,784 shs

Market Capitalization

$32.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of DarioHealth?

The following Wall Street sell-side analysts have issued reports on DarioHealth in the last twelve months: Alliance Global Partners, Craig Hallum, and Stifel Nicolaus.
View the latest analyst ratings for DRIO.

What is the current price target for DarioHealth?

3 Wall Street analysts have set twelve-month price targets for DarioHealth in the last year. Their average twelve-month price target is $6.03, suggesting a possible upside of 382.7%. Craig Hallum has the highest price target set, predicting DRIO will reach $8.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $4.10 for DarioHealth in the next year.
View the latest price targets for DRIO.

What is the current consensus analyst rating for DarioHealth?

DarioHealth currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DRIO will outperform the market and that investors should add to their positions of DarioHealth.
View the latest ratings for DRIO.

What other companies compete with DarioHealth?

Other companies that are similar to DarioHealth include LENSAR, Modular Medical, TriSalus Life Sciences, NeuroOne Medical Technologies and Retractable Technologies. Learn More about companies similar to DarioHealth.

How do I contact DarioHealth's investor relations team?

DarioHealth's physical mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company's listed phone number is (833) 914-3796 and its investor relations email address is [email protected]. The official website for DarioHealth is www.mydario.com. Learn More about contacing DarioHealth investor relations.